General MedicationsORALGeneric
VIDEX EC
DIDANOSINE
Standard Dose
400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Key Takeaways
- Primary indication: Review priority: STANDARD Marketing status: Discontinued
- Approval overview VIDEX EC is listed in Drugs@FDA under application 021183 (NDA).
- Review priority: STANDARD Marketing status: Discontinued Active ingredient DIDANOSINE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2018-12-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview VIDEX EC is listed in Drugs@FDA under application 021183 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient DIDANOSINE Form and strength CAPSULE, DELAYED REL PELLETS;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BRISTOL MYERS SQUIBB Submission history Latest submission status date: 2018-12-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.